What “Research Use Only” Means In Practice

Where the Designation Comes From

The Federal Food, Drug, and Cosmetic Act does not sort articles into categories by chemistry. Section 201(g)(1), codified at 21 U.S.C. 321(g)(1), defines a drug as, among other things, an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and an article (other than food) intended to affect the structure or any function of the body. The load-bearing word is intended. Two chemically identical vials can sit in different regulatory categories depending on the evidence of what the person responsible for their labeling meant them for. No substance is inherently a research material and no substance is inherently a drug; the classification attaches to a set of facts surrounding a particular article as offered by a particular party.

The phrase “Research Use Only” has one narrow formal home in U.S. law. Under 21 CFR 809.10(c), certain in vitro diagnostic products are exempted from the full IVD labeling requirements if they are in the laboratory research phase and are not represented as effective in vitro diagnostic products. Products in that phase must prominently bear the statement “For Research Use Only. Not for use in diagnostic procedures.” A parallel provision at 809.10(c)(2)(ii) covers the investigational phase and requires the statement “For Investigational Use Only. The performance characteristics of this product have not been established.”

Notice the direction of that logic. The exemption is conditioned on the product actually being in the research phase and on the absence of any representation that it works as a diagnostic. The label statement is a consequence of the product’s status, not a cause of it. Affixing the words does not place a product in the research phase any more than affixing a mileage sticker changes an odometer. Outside the IVD context — for bulk chemicals, reference standards, synthetic peptides, and similar materials — no federal regulation creates an RUO category at all. There is no application, no registration, no review, and no certificate. The phrase circulating on non-IVD supplier documentation is an industry convention borrowed from the IVD labeling rules, and the operative legal question underneath it remains the intended-use question posed by the statute.

What FDA’s RUO and IUO Guidance Actually Covers

FDA issued final guidance titled “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only” on November 25, 2013, under Docket No. FDA-2011-D-0305. It is addressed to manufacturers and distributors of RUO- and IUO-labeled IVD products, to any other entity that labels such products, and to FDA staff. The stated concern behind it is that unapproved and uncleared IVD products carrying RUO or IUO statements had in some cases been distributed while actually being intended for other purposes, including clinical diagnostic use, with the result that clinical decisions were being made on the basis of products whose performance characteristics were unproven and whose manufacturing controls were not designed to support consistent finished product.

The guidance’s central position is easy to state and easy to underestimate: RUO and IUO labeling must be consistent with the labeler’s actual intended use. The statement on the carton does not by itself establish that a product is confined to research. FDA evaluates the total picture — what the firm and its representatives say in writing and orally, how and to whom the product is offered, the kind of technical support provided, the settings and publications in which it appears — and where that picture points toward clinical diagnostic use, the product is treated as a device intended for that use regardless of the printed disclaimer.

Two qualifications matter for anyone reading the guidance outside its home domain. First, by its own terms it governs in vitro diagnostic products; it is not a general charter for research chemicals, and it should not be cited as though it were. Second, the analytical method it applies is not IVD-specific. It is the ordinary intended-use analysis that FDA applies across drugs and devices alike. That is why the document is widely read outside its formal scope: it is the clearest published articulation of how the agency reasons when a label says one thing and the surrounding conduct says another.

The Intended-Use Doctrine at 21 CFR 201.128

For drugs, the doctrine is codified at 21 CFR 201.128 (its device counterpart is 21 CFR 801.4). The regulation provides that “intended uses” refers to the objective intent of the persons legally responsible for the labeling of an article, or their representatives. Objective is the key qualifier. The inquiry is not into a private state of mind that a firm can assert or deny; it is into what a reasonable factfinder would infer from the record. The regulation lists the categories of proof: labeling claims, advertising matter, oral or written statements by those persons or their representatives, the design or composition of the article, and the circumstances surrounding its distribution — including circumstances in which the article is, with the firm’s knowledge, offered or used for a purpose for which it is neither labeled nor advertised.

The current text reflects the final rule “Regulations Regarding ‘Intended Uses,'” published at 86 Fed. Reg. 41383 on August 2, 2021. That rule added design or composition as an express evidentiary category and added a limiting clause providing that a firm would not be regarded as intending an unapproved new use for an approved drug based solely on that firm’s knowledge that the drug was being prescribed or used by health care providers for such use. Read carefully, that clause is narrow. It concerns an approved product, prescribing by licensed practitioners, and knowledge standing alone. It does not speak to unapproved materials, and it does not immunize knowledge that is accompanied by conduct facilitating the use. The regulation also states that intended uses can change after an article enters interstate commerce: a packer, distributor, or seller who intends an article for uses different from those intended by the party it was received from must supply labeling that accords with those new intended uses. A downstream seller can therefore generate an intended use of its own, independent of whatever the original manufacturer meant.

The consequences of establishing a human-therapeutic intended use are cumulative rather than singular. The article becomes a new drug requiring an approved application under 21 U.S.C. 355(a), and its introduction into interstate commerce without one is prohibited under 21 U.S.C. 331(d). It is also misbranded under 21 U.S.C. 352(f)(1) for want of adequate directions for use, which 21 CFR 201.5 defines as directions under which a layperson can use the article safely and for the purposes for which it is intended. The prescription-drug exemption from that requirement, at 21 U.S.C. 353(b)(1) and 21 CFR 201.100, is not available to an unapproved article. The practical corollary is counterintuitive but important: once a human intended use is established, supplying directions does not repair the misbranding. It supplies further evidence of the intent that created the problem. That is the structural reason a party responsible for labeling cannot confine its research-use position to a single line while publishing human-use or preparation-for-use content elsewhere in the materials it controls. The totality of the evidence includes every page a party publishes, not only the one bearing the disclaimer.

What the Designation Constrains on the Labeler’s Side

Read against 201.128, the discipline that a research-use position demands is broader than a single label line. It excludes any representation that the material diagnoses, treats, mitigates, cures, or prevents a disease, and any representation that it affects the structure or function of the body — the two statutory triggers, stated in the statute’s own vocabulary. It excludes human-use directions of every kind, whether framed as quantity, schedule, timing, or technique. It excludes preparation content framed as rendering material ready for use in a person, and it excludes technical support that helps a recipient carry out such a use. Implicit claims count as claims. Symptom vocabulary, testimonials, transformation imagery, calculators, and adjacency to consumer-health material can establish intent as effectively as an explicit sentence, and FDA has long read context rather than isolated sentences.

Distribution circumstances are part of the record too. Who the material is offered to, the channel it is offered through, what a representative writes in correspondence, what other content shares the same publication, and what the firm knows about how the material is actually being used all fall within the regulation’s language. A disclaimer that contradicts the rest of the record does not neutralize it. If anything, a boilerplate denial sitting alongside content that assumes human use tends to show awareness of the use rather than absence of intent.

What remains available is substantial and is the ordinary content of technical documentation: identity and structure, characterization data, analytical methods and their performance, physicochemical properties such as solubility behavior and ionization, measured stability under defined conditions, and hazard and handling information. The dividing line is durable and easy to apply in practice: describing what a substance is and how it behaves in an instrument is characterization; telling someone how to use it in a person is direction. The first is reference material. The second is evidence of intended use.

What Sits With the Receiving Laboratory

Nothing a supplier writes discharges an obligation that belongs to the institution receiving the material. Research involving human subjects is governed by the Federal Policy for the Protection of Human Subjects at 45 CFR part 46 and, where FDA-regulated products are involved, by 21 CFR parts 50 and 56, with review by a constituted IRB. A clinical investigation of a drug that is not approved for the use under study generally requires an investigational new drug application; the statutory hook is 21 U.S.C. 355(i) and the implementing regulations are at 21 CFR part 312. Work involving vertebrate animals runs through an IACUC under the Animal Welfare Act regulations and the PHS Policy on Humane Care and Use of Laboratory Animals. Work involving biological agents or recombinant material runs through an institutional biosafety committee, with containment practices drawn from Biosafety in Microbiological and Biomedical Laboratories. These are institutional determinations, made in advance, by bodies with jurisdiction over the investigator.

Hazard assessment is likewise local. OSHA’s Occupational Exposure to Hazardous Chemicals in Laboratories standard, 29 CFR 1910.1450, requires a written Chemical Hygiene Plan, defined control measures, and employee information and training; the Hazard Communication standard at 29 CFR 1910.1200 governs safety data sheets and their content. For novel or sparsely studied compounds, toxicological data are frequently thin or absent, and a safety data sheet may say little more than that. The absence of hazard data is not evidence of low hazard. The prudent practice for substances of unknown toxicity is to handle them under conservative assumptions until characterization exists, an approach set out in detail in the National Research Council’s Prudent Practices in the Laboratory.

Jurisdictional questions sit with the recipient as well. State controlled-substance schedules do not always track the federal schedules, and state law may regulate possession, distribution, or transfer independently. Import, export, transport classification, and waste disposal are separately regulated regimes with their own documentation. Professional licensure and state practice acts define what a licensed practitioner may lawfully do, and a research-use designation has no bearing on any of that. A laboratory that has satisfied itself on the technical merits of a material has not thereby satisfied itself on any of these questions.

Why the Label Is Not a Shield

The structural reason is the one already given: the designation is a representation made by the party responsible for the labeling, not a permission granted by a regulator. Because intent under 201.128 is established from the totality of the evidence, a label that the surrounding record contradicts is simply one document within that record, and not a privileged one. FDA says as much within its own IVD domain, and the reasoning generalizes because it is the general reasoning.

The same pattern appears outside the FDCA. The Controlled Substance Analogue Enforcement Act, at 21 U.S.C. 802(32)(A) and 813, directs that a substance substantially similar to a scheduled controlled substance be treated as a Schedule I substance to the extent it is intended for human consumption. In McFadden v. United States, 576 U.S. 186 (2015), the Supreme Court addressed the mental state the government must prove under 21 U.S.C. 841(a)(1) when the substance is an analogue, holding that the government must establish that the defendant knew he was dealing with a substance regulated under the Controlled Substances Act or the Analogue Act — either knowledge that the substance was controlled, or knowledge of the features that make it an analogue. The lesson for present purposes is not that any particular outcome follows from any particular label. It is that these are factual questions about knowledge and intent, resolved on the whole record, and that no statute makes a printed disclaimer dispositive in either direction.

The point runs in both directions. On the receiving side, obtaining material that carries a research-use designation confers no authority. It does not create an exemption from investigational-new-drug requirements, from institutional review, from state controlled-substance law, or from professional practice acts. It does not establish that the material’s identity, purity, or toxicity is known to anyone. It is a statement about the boundary of what one party is representing, and it leaves every other legal and scientific obligation exactly where it was.

Reading the Designation Honestly

Stated affirmatively, the designation communicates a narrow thing: the party offering the material represents it for laboratory investigation and makes no claim about its performance for any human, clinical, or diagnostic purpose. The investigational-use wording at 21 CFR 809.10(c)(2)(ii) makes the corresponding disclaimer explicit — that performance characteristics have not been established — and for research-phase material the same proposition holds a fortiori, since the article has not reached the stage where performance would be under evaluation at all.

Stated negatively, the designation is silent on nearly everything a working laboratory needs to know. It says nothing about identity, purity, potency, counterion content, residual solvent, water content, sterility, endotoxin, or stability; those are established by analysis and documentation, and a phrase on a label is not a substitute for either. It says nothing about hazard. It says nothing about whether any particular use is lawful in any particular jurisdiction, and it is not a determination by any agency that anything is safe or permitted. It does not function as a waiver, a consent, or a certification, and it does not travel with the material as a kind of license.

The practical test of whether a research-use position is real is whether the rest of the record agrees with it. If the technical description, the correspondence, the educational material, the imagery, and the audience all treat the substance as an object of measurement, the designation describes what is actually happening. If any of those treat it as something to be used in a person, the designation describes only what someone wished were happening, and under 21 CFR 201.128 it is the record that governs. Understood that way, the phrase is best read not as a status but as a boundary on representation — one that leaves intact every obligation that applied to the material before anyone printed a word on the vial.

References

1. Federal Food, Drug, and Cosmetic Act sec. 201(g)(1), codified at 21 U.S.C. sec. 321(g)(1) (statutory definition of “drug,” turning on intended use).
2. 21 C.F.R. sec. 201.128, Meaning of “intended uses” (objective intent shown by labeling claims, advertising, oral or written statements, design or composition, and circumstances surrounding distribution; downstream packers, distributors, and sellers may establish new intended uses). Device counterpart at 21 C.F.R. sec. 801.4.
3. Regulations Regarding “Intended Uses,” Final Rule, 86 Fed. Reg. 41383 (Aug. 2, 2021) (amending 21 C.F.R. secs. 201.128 and 801.4; adding design-or-composition evidence and the limiting clause on knowledge alone).
4. 21 C.F.R. sec. 809.10(c), Labeling for in vitro diagnostic products: research-phase statement at sec. 809.10(c)(2)(i) (“For Research Use Only. Not for use in diagnostic procedures.”) and investigational-phase statement at sec. 809.10(c)(2)(ii) (“For Investigational Use Only. The performance characteristics of this product have not been established.”).
5. U.S. Food and Drug Administration, Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff, issued November 25, 2013; Docket No. FDA-2011-D-0305.
6. 21 U.S.C. sec. 331(d) and sec. 355(a) (prohibition on introducing an unapproved new drug into interstate commerce); 21 U.S.C. sec. 355(i) and 21 C.F.R. part 312 (investigational new drug exemption and implementing regulations).
7. 21 U.S.C. sec. 352(f)(1) (misbranding for lack of adequate directions for use); 21 C.F.R. sec. 201.5 (definition of adequate directions for use); 21 U.S.C. sec. 353(b)(1) and 21 C.F.R. sec. 201.100 (prescription-drug exemption conditions).
8. Controlled Substance Analogue Enforcement Act of 1986, 21 U.S.C. secs. 802(32)(A) and 813 (analogues treated as Schedule I controlled substances to the extent intended for human consumption).
9. McFadden v. United States, 576 U.S. 186 (2015) (mental-state element under 21 U.S.C. sec. 841(a)(1) where the substance is an analogue).
10. 45 C.F.R. part 46, Federal Policy for the Protection of Human Subjects (Common Rule); 21 C.F.R. parts 50 and 56 (FDA informed consent and institutional review board regulations).
11. 29 C.F.R. sec. 1910.1450, Occupational Exposure to Hazardous Chemicals in Laboratories (Chemical Hygiene Plan requirement); 29 C.F.R. sec. 1910.1200, Hazard Communication (safety data sheets).
12. National Research Council, Prudent Practices in the Laboratory: Handling and Management of Chemical Hazards, updated version (Washington, DC: The National Academies Press, 2011). DOI 10.17226/12654.
13. U.S. Centers for Disease Control and Prevention and National Institutes of Health, Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th edition (2020).
14. Animal Welfare Act regulations, 9 C.F.R. chapter I, subchapter A; Public Health Service Policy on Humane Care and Use of Laboratory Animals (institutional animal care and use committee review).